S-Nitrosocysteine

HCID 9793848

Teilstruktursuche Ähnliche Strukturen suchen

Grundinformationen

CAS: 51209-75-7
Standard-SMILES: N[C@@H](CSN=O)C(=O)O
InChIKey: XOWVFANEOZMPKG-REOHCLBHSA-N
Summenformel: C3H6N2O3S
Durchschnittliche Molmasse: 150,16 g/mol

Überblick

S-nitroso-L-cysteine is an L-cysteine derivative in which the sulfur atom carries a nitroso substituent. A cell-permeable low-molecular-weight nitrosothiol and nitric oxide donor. It has a role as a vasodilator agent, a hematologic agent and a platelet aggregation inhibitor. It is a nitrosothio compound and a L-cysteine derivative.

Namen und Bezeichner

Bevorzugter Name: S-Nitrosocysteine
IUPAC: (2R)-2-amino-3-nitrososulfanylpropanoic acid

Namen und Synonyme

S-NitrosocysteineNitrosocysteineS-Nitroso-L-cysteine51209-75-7L-S-nitrosocysteineCHEBI:138935926P2322P4L-SNC compoundSNC compoundDTXSID40965482RefChem:180703DTXCID801393151

Weitere Namen anzeigen

s-nitroso-cysteine(2R)-2-amino-3-nitrososulfanylpropanoic acidS-Nitroso-L-CysteinNO-cysteineCysNONO-L-cysteineL-CysSNOEpitope ID:735795

Datenbank-Bezeichner

CAS: 51209-75-7
PubChem CID: 9793848
ChEMBL: CHEMBL300676
ChEBI: CHEBI:138935
UNII: 926P2322P4
Nikkaji: J293.778F

Eigenschaften

Berechnete Struktureigenschaften

XLogP: -3,4
Polarare Oberfläche (TPSA): 118 Å²
H-Brücken-Donoren: 2
H-Brücken-Akzeptoren: 6
Frei drehbare Bindungen: 3
Schwere Atome: 9
Formalladung: 0
Komplexität: 118

Chemie und Industrie

Pharmakologische Informationen

MeSH Pharmacological Classification · 3 Einträge

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Drugs used to cause dilation of the blood vessels.

A diverse group of agents, with unique chemical structures and biochemical requirements, which generate NITRIC OXIDE. These compounds have been used in the treatment of cardiovascular diseases and the management of acute myocardial infarction, acute and chronic congestive heart failure, and surgical control of blood pressure. (Adv Pharmacol 1995;34:361-81)